RayKnowChina Research Map
Shortlist

ShanghaiShanghai University of Traditional Chinese Medicine

Longhua Hospital

上海中医药大学附属龙华医院

Listed for 16 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Longhua Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌7 papers led
  2. Hepatocellular carcinoma肝细胞癌11 papers led
  3. Stomach cancer胃癌13 papers led
  4. Lung cancer肺癌44 papers led
  5. Breast cancer乳腺癌36 papers led
  6. Chordoma脊索瘤1 paper led
  7. Osteosarcoma骨肉瘤4 papers led
  8. Neuroblastoma神经母细胞瘤1 paper led
  9. Haemophilia A血友病 A1 paper led
  10. Coronary heart disease冠心病5 papers led1 open trial led
  11. Scoliosis脊柱侧弯2 papers led
  12. Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
  13. IgA nephropathyIgA 肾病1 paper led
  14. Primary biliary cholangitis原发性胆汁性胆管炎2 papers led
  15. Primary sclerosing cholangitis原发性硬化性胆管炎0 papers led
  16. Familial adenomatous polyposis家族性腺瘤性息肉病1 paper led

Not listed for: Nasopharyngeal carcinoma, Pancreatic cancer, Glioma, Hepatoblastoma, Retinoblastoma, Gastrointestinal stromal tumour, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Lymphoma, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Congenital heart disease, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 7 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 1120232024: 1120242025: 222025

18 hospitals in Shanghai for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesMolecular markers & genomicsImmunotherapy

Over half of these papers are lab or animal studies.

Papers it led7
  1. High antigen-presenting CAF levels correlate with reduced glycosaminoglycan biosynthesis-heparan sulfate/heparin metabolism in immune cells and poor prognosis in esophageal squamous cell carcinoma: Insights from bulk and single-cell transcr2025International journal of biological macromolecules
  2. Reversal of amino acid metabolism patterns between circulating blood and tumors as a new biomarker for the Zhengxu Xieshi syndrome in patients with esophageal squamous cell carcinoma.2025Journal of traditional Chinese medicine = Chung i tsa chih ying wen panFree full text
  3. Unveiling the methionine cycle: a key metabolic signature and NR4A2 as a methionine-responsive oncogene in esophageal squamous cell carcinoma.2024Cell death and differentiationFree full text
  4. Evodiamine inhibits ESCC by inducing M-phase cell-cycle arrest via CUL4A/p53/p21 axis and activating noxa-dependent intrinsic and DR4-dependent extrinsic apoptosis.2023Phytomedicine : international journal of phytotherapy and phytopharmacology
  5. New Metabolic Alterations and A Predictive Marker Pipecolic Acid in Sera for Esophageal Squamous Cell Carcinoma.2022Genomics, proteomics & bioinformaticsFree full text
  6. Daurisoline Inhibits ESCC by Inducing G1 Cell Cycle Arrest and Activating ER Stress to Trigger Noxa-Dependent Intrinsic and CHOP-DR5-Dependent Extrinsic Apoptosis via p-eIF2α-ATF4 Axis.2022Oxidative medicine and cellular longevityFree full text
  7. A multi-omics study delineates new molecular features and therapeutic targets for esophageal squamous cell carcinoma.2021Clinical and translational medicineFree full text
More papers found outside PubMed (not counted)1
  1. Long non-coding RNA NCK1-AS1 functions as a ceRNA to regulate cell viability and invasion in esophageal squamous cell carcinoma via microRNA-133b/ENPEP axis2022Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 11 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.07%.

Papers led
11
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 2220232024: 2220242025: 442025

16 hospitals in Shanghai for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesSurgery & liver transplantLocal treatment (ablation, TACE, HAIC)Immunotherapy & targeted drugs
Departments in papersMedical oncologyGastroenterology / hepatologyRadiology / nuclear medicineClinical trials / research unit

Over half of these papers are lab or animal studies.

Papers it led11
  1. Decoding the epigenetic-immune nexus in hepatocellular carcinoma: a Mendelian randomization study reveals BTN3A2, S100A12 and TRIM27 as white blood cell regulators.2025BMC cancerFree full text
  2. Gut Microbiota and Hepatocellular Carcinoma: Metabolic Products and Immunotherapy Modulation.2025Cancer medicineFree full text
  3. ERG mediates the differentiation of hepatic progenitor cells towards immunosuppressive PDGFRα+ cancer-associated fibroblasts during hepatocarcinogenesis.2025Cell death & diseaseFree full text
  4. FABP5+ lipid-loaded macrophages process tumour-derived unsaturated fatty acid signal to suppress T-cell antitumour immunity.2025Journal of hepatology
  5. SCFFBXW5-mediated degradation of AQP3 suppresses autophagic cell death through the PDPK1-AKT-MTOR axis in hepatocellular carcinoma cells.2024AutophagyFree full text
  6. Therapeutic potential of traditional Chinese medicine in the prevention and treatment of digestive inflammatory cancer transformation: Portulaca oleracea L. as a promising drug.2024Journal of ethnopharmacology
  7. Circ_0004913 Inhibits Cell Growth, Metastasis, and Glycolysis by Absorbing miR-184 to Regulate HAMP in Hepatocellular Carcinoma.2023Cancer biotherapy & radiopharmaceuticals
  8. Exploring the mechanism of Jianpi Huatan recipe in protecting hepatocellular carcinoma based on network pharmacology.2023Journal of ethnopharmacology
  9. Dual-Energy Computed Tomography Imaging in Early-Stage Hepatocellular Carcinoma: A Preliminary Study.2022Contrast media & molecular imagingFree full text
  10. Quantitative dual-energy computed tomography texture analysis predicts the response of primary small hepatocellular carcinoma to radiofrequency ablation.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  11. Case Report: Antiangiogenic Therapy Plus Immune Checkpoint Inhibitors Combined With Intratumoral Cryoablation for Hepatocellular Carcinoma.2021Frontiers in immunologyFree full text
All its trials on ClinicalTrials.gov, any status2
  1. Clinical Study of Targeted Cryoablation Therapy in the Treatment of Hepatic CarcinomaStatus unknownNCT02969096Lead (inferred)Phase 2Start 2016-10
  2. YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)CompletedNCT04000737Study sitePhase 2Start 2020-01

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 13 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
13
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 2220222023: 1120232024: 5520242025: 222025

17 hospitals in Shanghai for stomach cancer211 hospitals in China for stomach cancer

No open trial on stomach cancer lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImmunotherapy & targeted drugsImaging & AIPeritoneal spread & advanced disease
Departments in papersMedical oncologyGastroenterology / hepatologyPathology / laboratory medicine
Papers it led13
  1. Morin inhibits ubiquitination degradation of BCL-2 associated agonist of cell death and synergizes with BCL-2 inhibitor in gastric cancer cells.2025Journal of integrative medicine
  2. Potential of traditional Chinese medicine in managing and preventing Helicobacter pylori infection in Chinese military.2025World journal of gastroenterologyFree full text
  3. Chinese Medicine Prolongs Overall Survival of Chinese Patients with Advanced Gastric Cancer: Treatment Pattern and Survival Analysis of a 20-Year Real-World Study.2024Chinese journal of integrative medicine
  4. NRF2 inhibits RSL3 induced ferroptosis in gastric cancer through regulation of AKR1B1.2024Experimental cell research
  5. Chronic atrophic gastritis and risk of incident upper gastrointestinal cancers: a systematic review and meta-analysis.2024Journal of translational medicineFree full text
  6. ARID1A is a coactivator of STAT5 that contributes to CD8+ T cell dysfunction and anti-PD-1 resistance in gastric cancer.2024Pharmacological research
  7. Evaluating the efficacy of immunotherapy in gastric cancer: Insights from immune checkpoint inhibitors.2024World journal of gastroenterologyFree full text
  8. Efficacy of luteolin on the human gastric cancer cell line MKN45 and underlying mechanism.2023Journal of traditional Chinese medicine = Chung i tsa chih ying wen panFree full text
  9. Acacetin inhibits invasion, migration and TGF-β1-induced EMT of gastric cancer cells through the PI3K/Akt/Snail pathway.2022BMC complementary medicine and therapiesFree full text
  10. Effects of traditional Chinese medicine collaborative model (TCMCM) combined with adjuvant chemotherapy on IIIb and IIIc gastric cancer: a protocol for a randomized controlled trial.2022TrialsFree full text
  11. Clinic-Pathological Characteristics and Prognostic Value of PD-L1 and HER2 in Gastric Cancer.2021DNA and cell biology
  12. Drug metabolism-related eight-gene signature can predict the prognosis of gastric adenocarcinoma.2021Journal of clinical laboratory analysisFree full text
  13. Predicting gastric cancer outcome from resected lymph node histopathology images using deep learning.2021Nature communicationsFree full text
All its trials on ClinicalTrials.gov, any status2
  1. The Effect of Traditional Chinese Treatment Combined Adjuvant Chemotherapy in IIIb and IIIc Gastric CancerCompletedNCT03607656Lead (inferred)Phase 2/Phase 3Start 2018-06
  2. Effect Study of Clinical Outcomes of Traditional Chinese Medicine to Advanced Gastric Cancer by Propensity ScoreStatus unknownNCT02781285Lead (inferred)Start 2014-12

Run the PubMed searchClinicalTrials.gov

Cancer

Lung cancer

肺癌

Led 44 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
44
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 8820212022: 6620222023: 9920232024: 131320242025: 662025

22 hospitals in Shanghai for lung cancer251 hospitals in China for lung cancer

No open trial on lung cancer lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersMedical oncologyRadiology / nuclear medicineRadiation oncology

Over half of these papers are lab or animal studies.

Papers it led44
  1. Formosanin C inhibits infiltration of MDSCs by activating the STING pathway in non-small cell lung cancer.2026International immunopharmacology
  2. Amentoflavone from Ginkgo biloba inhibits EMT-driven lung cancer metastasis by targeting TGFBR2: Integrative network pharmacology, machine learning, and experimental validation.2026Journal of ethnopharmacology
  3. Opportunistic muscle density assay during CT lung cancer screening for low muscle quality evaluation in older adults: a multicenter study.2025Aging clinical and experimental researchFree full text
  4. Treatment of Tislelizumab-Induced Toxic Epidermal Necrolysis and Agranulocytosis: A Case Report and Literature Review.2025Current drug safetyFree full text
  5. Local anesthetic ropivacaine inhibits non-small cell lung cancer progression by modulating the hsa_circ_0001320/miR-518a-5p axis.2025HereditasFree full text
  6. YinxingGujin decoction suppresses lung adenocarcinoma metastasis by modulating the TGF-β/STAT3/PD-L1 Axis: Network pharmacology and experimental validation.2025Journal of ethnopharmacology
  7. Jiawei Yanghe Decoction augments intratumoral CD8+ TIL infiltration and enhances radiotherapy efficacy in non-small cell lung cancer through CXCR3 ligand-mediated chemotaxis.2025Journal of ethnopharmacology
  8. Role of Traditional Chinese Medicine in Lung Cancer Management: A Review.2025The American journal of Chinese medicine
  9. Development of crizotinib-associated renal cyst in a non-small cell lung cancer patient with ALK fusion: a case report and review of the literature.2024Diagnostic pathologyFree full text
  10. SENP2-NDR2-p21 axis modulates lung cancer cell growth.2024European journal of pharmacology
  11. Oral Decoctions Based on Qi-Yin Syndrome Differentiation After Adjuvant Chemotherapy in Resected Stage ΙΙΙA Non-Small Cell Lung Cancer: A Randomized Controlled Trial.2024Integrative cancer therapiesRCTFree full text
  12. Differential prognostic impact and potential molecular mechanisms of PCDHGA12 expression in lung adenocarcinoma and squamous cell carcinoma.2024International immunopharmacology
  13. A commentary on 'Impact of lymphadenectomy extent on immunotherapy efficacy in postresectional recurred non-small cell lung cancer: a multi-institutional retrospective cohort study'.2024International journal of surgery (London, England)Free full text
  14. Synergetic approaches of fucoidan and trabectedin complex coated PLGA nanoparticles effectively suppresses proliferation and induce apoptosis for the treatment on non-small cell lung cancer.2024Journal of biomaterials science. Polymer edition
  15. Integrating single-cell and multi-omic approaches reveals Euphorbiae Humifusae Herba-dependent mitochondrial dysfunction in non-small-cell lung cancer.2024Journal of cellular and molecular medicineFree full text
  16. Cycloastragenol induces apoptosis and protective autophagy through AMPK/ULK1/mTOR axis in human non-small cell lung cancer cell lines.2024Journal of integrative medicine
  17. Comment on "Passive Smoking-Induced Mutagenesis as a Promoter of Lung Carcinogenesis".2024Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  18. Suggestions for the predictive factors related to irAES and research methods during dose switching of pembrolizumab treatment in patients with advanced NSCLC.2024Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  19. A pilot study of precision treatment for patients with lung cancer pain by Longteng Tongluo recipe using serum genomics.2024Journal of traditional Chinese medicine = Chung i tsa chih ying wen panRCTFree full text
  20. Significance of NKX2-1 as a biomarker for clinical prognosis, immune infiltration, and drug therapy in lung squamous cell carcinoma.2024PeerJFree full text
  21. Study on the difference and regularity of tongue images in 309 patients with different pathological stages of non-small cell lung cancer.2024Technology and health care : official journal of the European Society for Engineering and MedicineFree full text
  22. Acute myocardial infarction due to coronary embolism caused by a metastatic mass from lung cancer.2023BMC cardiovascular disordersFree full text
  23. Exosomal lncRNA HOTAIR promotes osteoclast differentiation by targeting TGF-β/PTHrP/RANKL pathway.2023Basic & clinical pharmacology & toxicology
  24. Fructose utilization enhanced by GLUT5 promotes lung cancer cell migration via activating glycolysis/AKT pathway.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  25. Prognostic factors and outcomes of surgical intervention for patients with spinal metastases secondary to lung cancer: an update systematic review and meta analysis.2023European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research SocietyFree full text
  26. Design strategy and research progress of multifunctional nanoparticles in lung cancer therapy.2023Expert opinion on investigational drugs
  27. Identification and validation of a novel cuproptosis-related stemness signature to predict prognosis and immune landscape in lung adenocarcinoma by integrating single-cell and bulk RNA-sequencing.2023Frontiers in immunologyFree full text
  28. Platycodin D induces neutrophil apoptosis by downregulating PD-L1 expression to inhibit breast cancer pulmonary metastasis.2023International immunopharmacology
  29. In stage IV pulmonary adenocarcinoma patients, treatment with Traditional Chinese Medicine alone gives prognostically superior results to treatment with Platinum-Based Chemotherapy alone.2023Phytomedicine : international journal of phytotherapy and phytopharmacology
  30. Active post-transcriptional regulation and ACLY-mediated acetyl-CoA synthesis as a pivotal target of Shuang-Huang-Sheng-Bai formula for lung adenocarcinoma treatment.2023Phytomedicine : international journal of phytotherapy and phytopharmacology
  31. Camptothecin-Loaded and Manganese Dioxide-Coated Polydopamine Nanomedicine Used for Magnetic Resonance Imaging Diagnosis and Chemo-Photothermal Therapy for Lung Cancer.2022International journal of nanomedicineFree full text
  32. A novel model based on liquid-liquid phase separation-Related genes correlates immune microenvironment profiles and predicts prognosis of lung squamous cell carcinoma.2022Journal of clinical laboratory analysisFree full text
  33. Feiyanning downregulating CXCLs/CXCR2 axis to suppress TANs infiltration in the prevention of lung cancer metastasis.2022Journal of ethnopharmacology
  34. Mechanism underlying the effect of Liujunzi decoction on advanced-stage non-small cell lung cancer in patients after first-line chemotherapy.2022Journal of traditional Chinese medicine = Chung i tsa chih ying wen panFree full text
  35. Simultaneous development of pneumonitis and autoimmune diabetes secondary to immune checkpoint inhibitor treatment with durvalumab in an advanced small cell lung cancer patient: A case report.2022MedicineFree full text
  36. To study the mechanism of Scutellariae Radix and Astragaloside in the treatment of lung cancer based on network pharmacology.2022MedicineFree full text
  37. Paclitaxel-loaded and folic acid-modified PLGA nanomedicine with glutathione response for the treatment of lung cancer.2021Acta biochimica et biophysica Sinica
  38. Ruyiping extract reduces lung metastasis in triple negative breast cancer by regulating macrophage polarization.2021Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  39. Multidisciplinary and Comprehensive Chinese Medicine for Advanced Non-Small Cell Lung Cancer Patients: A Retrospective Study of 855 Cases.2021Chinese journal of integrative medicine
  40. Combined Treatment with JFKD and Gefitinib Overcomes Drug Resistance in Non-Small Cell Lung Cancer.2021Current pharmaceutical biotechnology
  41. Chinese herbal medicine Feiyanning cooperates with cisplatin to enhance cytotoxicity to non-small-cell lung cancer by inhibiting protective autophagy.2021Journal of ethnopharmacology
  42. Jinfukang inhibits lung cancer metastasis by upregulating CX3CL1 to recruit NK cells to kill CTCs.2021Journal of ethnopharmacology
  43. Jinfukang regulates integrin/Src pathway and anoikis mediating circulating lung cancer cells migration.2021Journal of ethnopharmacology
  44. Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report.2021MedicineFree full text
Chinese-language papers (not in the count)1
  1. [The TCR repertoire diversity and its application in the prevention and treatment of lung cancer].2022Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
All its trials on ClinicalTrials.gov, any status2
  1. Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Retrospective StudyStatus unknownNCT04397432Study siteStart 2020-08
  2. Clinical Trial of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC)Status unknownNCT03986528Study sitePhase 4Start 2019-08

Run the PubMed searchClinicalTrials.gov

Cancer

Breast cancer

乳腺癌

Led 36 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
36
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 7720212022: 8820222023: 6620232024: 7720242025: 772025

19 hospitals in Shanghai for breast cancer219 hospitals in China for breast cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
    Phase
    Phase 4
    Started
    2021-06
    Posted
    Registry
    NCT04790305

    Age 18 years to 70 years (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 26 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Wuhan, Xi'an, Yangzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyRadiology / nuclear medicinePathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led36
  1. Nobiletin and polydatin synergistically alleviate triple-negative breast cancer liver metastasis via suppressing ECM1a-mediated fatty acid biosynthesis.2026Acta pharmacologica Sinica
  2. Transcription factor occupancy limits DNA methylation and determines ICAM1 expression in breast cancer.2025Acta biochimica et biophysica SinicaFree full text
  3. Integrin β1 in breast cancer: mechanisms of progression and therapy.2025Breast cancer (Tokyo, Japan)
  4. Elucidating the Pharmacological Basis of Xianling Cifang Granules Against Breast Cancer. A Metabolomic Profiling Study.2025Drug design, development and therapyFree full text
  5. Multiparametric MRI for differentiating idiopathic granulomatous mastitis from invasive breast cancer:Improving radiologists' diagnostic accuracy.2025European journal of radiology
  6. A pharmacokinetic study of four bone-protective compounds after oral administration of WSZG extract in primary breast cancer mice.2025Journal of pharmaceutical and biomedical analysis
  7. Wenshen Zhuanggu Fang reduces breast cancer bone metastasis by regulating macrophage polarization: a bioinformatics analysis combined with experimental validation.2025Journal of traditional Chinese medicine = Chung i tsa chih ying wen panFree full text
  8. Impact of serum lipids on prognosis in breast cancer patients: a systematic review and meta-analysis.2025World journal of surgical oncologyFree full text
  9. Integrated network pharmacology and experimental verification to explore the potential mechanism of San Ying decoction for treating triple-negative breast cancer.2024Acta biochimica et biophysica SinicaFree full text
  10. Xianling Lianxia formula enhances the inhibitory effects of trastuzumab on HER2-positive breast cancer.2024Acta biochimica et biophysica SinicaFree full text
  11. Non-pharmaceutical interventions for depressive symptoms in patients with breast cancer: protocol for a systematic review and network meta-analysis.2024BMJ openFree full text
  12. Comprehensive review of drug-mediated ICD inhibition of breast cancer: mechanism, status, and prospects.2024Clinical and experimental medicineFree full text
  13. OSU-T315 overcomes immunosuppression in triple-negative breast cancer by targeting the ILK/NF-κB signaling pathway to enhance immunotherapeutic efficacy.2024International immunopharmacology
  14. Association between red cell distribution width and all-cause mortality in patients with breast cancer: A retrospective analysis using MIMIC-IV 2.0.2024PloS oneFree full text
  15. Tumor-derived exosomal ICAM1 promotes bone metastasis of triple-negative breast cancer by inducing CD8+ T cell exhaustion.2024The international journal of biochemistry & cell biology
  16. Non-pharmaceutical interventions in complementary and alternative medicine for insomnia in breast cancer survivors: a protocol for a systematic review and network meta-analysis.2023BMJ openFree full text
  17. Xianlinglianxiafang Inhibited the growth and metastasis of triple-negative breast cancer via activating PPARγ/AMPK signaling pathway.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  18. Benign breast disease with malignant imaging features: a case report.2023Journal of medical case reportsFree full text
  19. Molecular mechanism of Ruxian Shuhou prescription in the treatment of triple-negative breast cancer based on network pharmacology.2023MedicineFree full text
  20. Development and validation of novel defined pyroptosis-related gene signature for progression-free survival prediction in patients with breast invasive carcinoma.2023Minerva surgery
  21. Citri Reticulatae Pericarpium-Reynoutria japonica Houtt. herb pair suppresses breast cancer liver metastasis by targeting ECM1-mediated cholesterol biosynthesis pathway.2023Phytomedicine : international journal of phytotherapy and phytopharmacology
  22. Osthole inhibits the migration and invasion of highly metastatic breast cancer cells by suppressing ITGα3/ITGβ5 signaling.2022Acta pharmacologica SinicaFree full text
  23. Efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, advanced breast cancer: a systematic review and meta-analysis.2022Annals of palliative medicine
  24. ICAM1 promotes bone metastasis via integrin-mediated TGF-β/EMT signaling in triple-negative breast cancer.2022Cancer scienceFree full text
  25. Primary highly differentiated breast angiosarcoma in an adolescent girl.2022European review for medical and pharmacological sciences
  26. Cancer Risk in Hashimoto's Thyroiditis: a Systematic Review and Meta-Analysis.2022Frontiers in endocrinologyFree full text
  27. Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer.2022Frontiers in immunologyFree full text
  28. MY11 exerts antitumor effects through activation of the NF-κB/PUMA signaling pathway in breast cancer.2022Investigational new drugsFree full text
  29. Identifying the anti-metastasis effect of Anhydroicaritin on breast cancer: Coupling network pharmacology with experimental validation.2022Journal of ethnopharmacology
  30. Formononetin relieves the facilitating effect of lncRNA AFAP1-AS1-miR-195/miR-545 axis on progression and chemo-resistance of triple-negative breast cancer.2021AgingFree full text
  31. Ruyiping formula inhibits metastasis via the microRNA-134-SLUG axis in breast cancer.2021BMC complementary medicine and therapiesFree full text
  32. Ruyiping extract reduces lung metastasis in triple negative breast cancer by regulating macrophage polarization.2021Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  33. Polysaccharide-rich extract from Polygonatum sibiricum protects hematopoiesis in bone marrow suppressed by triple negative breast cancer.2021Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  34. Qigong for women with breast cancer: An updated systematic review and meta-analysis.2021Complementary therapies in medicine
  35. Comprehensive Analysis of Prognostic and Immune Infiltrates for RAD51 in Human Breast Cancer.2021Critical reviews in eukaryotic gene expression
  36. The Impact of Platinum-Containing Chemotherapies in Advanced Triple-Negative Breast Cancer: Meta-Analytical Approach to Evaluating Its Efficacy and Safety.2021Oncology research and treatment
All its trials on ClinicalTrials.gov, any status3
  1. Clinical Study on Auricular Points Sticking Plus Chinese Medication for Hot Flashes in Breast Cancer WomenStatus unknownNCT03540251Lead sponsorN/AStart 2019-01
  2. Efficacy of Acupuncture Treatment for Breast Cancer-associated InsomniaActive, not recruitingNCT05510700Lead (inferred)N/AStart 2022-10
  3. Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast CancerRecruitingNCT04790305Study sitePhase 4Start 2021-06

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led 1 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 0.9%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

14 hospitals in Shanghai for chordoma84 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 4 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 2220242025: 002025

45 hospitals in Shanghai for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

27 hospitals in Shanghai for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 1 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

9 hospitals in Shanghai for haemophilia A132 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Coronary heart disease

冠心病

Led 5 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 0.1%.

Papers led
5
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 3320222023: 1120232024: 0020242025: 112025

17 hospitals in Shanghai for coronary heart disease231 hospitals in China for coronary heart disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Chaigui Longmu Ejiao Paste for Ischemic Heart Disease
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07478328

    Age 18 years to 75 years (registered criteria)

    Led by Longhua HospitalShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Other diseases

Scoliosis

脊柱侧弯

Led 2 of the 925 English-language PubMed papers on scoliosis with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

12 hospitals in Shanghai for scoliosis107 hospitals in China for scoliosis

No open trial on scoliosis lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

26 hospitals in Shanghai for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

23 hospitals in Shanghai for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology
Papers it led1
  1. Clinicopathological Characteristics and Outcomes of Immunoglobulin A Nephropathy with Different Types of Dyslipidemia: A Retrospective Single-Center Study.2023Kidney & blood pressure researchFree full text
Earlier papers (2016–2020)1
  1. Personalized evaluation based on quantitative proteomics for drug-treated patients with chronic kidney disease.2016Journal of molecular cell biologyRCT
All its trials on ClinicalTrials.gov, any status2
  1. Integrative Medicine of IgA NephropathyStatus unknownNCT02712697Lead (inferred)N/AStart 2016-06
  2. Study of Standardized Treatment of Integrative Medicine With the Severe IgA NephropathStatus unknownNCT01879514Lead (inferred)N/AStart 2010-01

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 2 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

16 hospitals in Shanghai for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led no English-language PubMed papers on primary sclerosing cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

13 hospitals in Shanghai for primary sclerosing cholangitis89 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led 1 of the 59 English-language PubMed papers on familial adenomatous polyposis with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

9 hospitals in Shanghai for familial adenomatous polyposis74 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

上海中医药大学附属龙华医院

Longhua Hospital

上海

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Longhua Hospital Shanghai University of Traditional Chinese Medicine; Shanghai Longhua Hospital; LongHua Hospital

Suggest a correctionDownload the data